Dassault Systèmes’ Living Heart Project Reaches Next Milestones In Mission To Improve Patient Care

Dassault Systèmes’ Living Heart Project Reaches Next Milestones In Mission To Improve Patient Care

Florida, US: Dassault Systèmes has outlined, at the 3DEXPERIENCE Forum North America, multiple milestones in its Living Heart Project aimed to drive the creation and use of simulated 3D personalised hearts in the treatment, diagnosis and prevention of heart diseases. As the scientific and medical community seeks faster and more targeted ways to improve patient care, the Living Heart Project is extending its reach through new partnerships and applications while lowering the barriers to access.

The Living Heart is now available through the 3DEXPERIENCE platform on the cloud, offering the speed and flexibility of High-Performance Computing (HPC) to even the smallest medical device companies. Any life sciences company can immediately access a complete, on-demand HPC environment to scale up virtual testing securely and collaboratively while managing infrastructure costs. This also crosses an important boundary toward the use of the Living Heart directly in a clinical setting.

The Living Heart Project has grown to more than 95 member organisations worldwide including medical researchers, practitioners, device manufacturers and regulatory agencies united in a mission of open innovation to solve healthcare challenges. The project has supported 15 research grant proposals by providing access to the model, associated technologies and project expertise. Novel use of the model to understand heart disease and study the safety and effectiveness of medical devices has appeared in eight articles published in peer-reviewed journals to date.

Advertisments

For the first time, the Living Heart was used to simulate detailed drug interactions affecting the entire organ function. Researchers at Stanford University working with UberCloud recently used the Living Heart as a platform for a model that would enable pharmaceutical companies to test drugs for the risk of inducing cardiac arrhythmias, the leading negative side effect preventing FDA approval.

READ MORE INDUSTRY NEWS

WANT MORE INSIDER NEWS? SUBSCRIBE TO IAA NOW!

CHECK OUT IAA’S CURRENT AND PAST ISSUES: DIGITAL MAGAZINE

Siemens Showcases Digitalisation Applications For Machine And Plant Builders
Qualcomm And Mercedes-AMG Petronas Motorsport Extend Strategic Partnership Focusing On High-Speed Communications And Wireless Power